The US Food and Drug Administration has expanded the approved indications for Boston Scientific’s SYNERGY BP everolimus-eluting platinum chromium coronary stent to include patients at high risk for bleeding, the company announced on 11 August.
This labeling expansion makes SYNERGY BP the first and only stent platform approved in the US for patients at...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?